Amanda M Fretts1,2, Paul N Jensen2,3, Andrew Hoofnagle4, Barbara McKnight2,5, Barbara V Howard6,7, Jason Umans6, Chaoyu Yu5, Colleen Sitlani2,3, David S Siscovick8, Irena B King9, Nona Sotoodehnia2,3, Rozenn N Lemaitre2,3. 1. Department of Epidemiology, University of Washington, Seattle, WA, USA. 2. Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA. 3. Department of Medicine, University of Washington, Seattle, WA, USA. 4. Department of Laboratory Medicine, University of Washington, Seattle, WA, USA. 5. Department of Biostatistics, University of Washington, Seattle, WA, USA. 6. MedStar Health Research Institute, Hyattsville, MD, USA. 7. Georgetown and Howard Universities Center for Translational Science, Washington, DC, USA. 8. New York Academy of Medicine, New York, NY, USA. 9. Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.
Abstract
BACKGROUND: Few studies have assessed the associations of ceramides and sphingomyelins (SMs) with diabetes in humans. OBJECTIVE: We assessed associations of 15 circulating ceramides and SM species with incident diabetes in 2 studies. METHODS: The analysis included 435 American-Indian participants from the Strong Heart Study (nested case-control design for analyses; mean age: 57 y; 34% male; median time until diabetes 4.3 y for cases) and 1902 participants from the Strong Heart Family Study (prospective design for analyses; mean age: 37 y; 39% male; median 12.5 y of follow-up). Sphingolipid species were measured using stored plasma samples by sequential LC and MS. Using logistic regression and parametric survival models within studies, and an inverse-variance-weighted meta-analysis across studies, we examined associations of 15 ceramides and SM species with incident diabetes. RESULTS: There were 446 cases of incident diabetes across the studies. Higher circulating concentrations of ceramides containing stearic acid (Cer-18), arachidic acid (Cer-20), and behenic acid (Cer-22) were each associated with a higher risk of diabetes. The RRs for incident diabetes per 1 SD of each log ceramide species (μM) were 1.22 (95% CI: 1.09, 1.37) for Cer-18, 1.18 (95% CI: 1.06, 1.31) for Cer-20, and 1.20 (95% CI: 1.08, 1.32) for Cer-22. Although the magnitude of the risk estimates for the association of ceramides containing lignoceric acid (Cer-24) with diabetes was similar to those for Cer-18, Cer-20, and Cer-22 (RR = 1.13; 95% CI: 1.01, 1.26), the association was not statistically significant after correction for multiple testing (P = 0.007). Ceramides carrying palmitic acid (Cer-16), SMs, glucosyl-ceramides, or a lactosyl-ceramide were not associated with diabetes risk. CONCLUSIONS: Higher concentrations of circulating Cer-18, Cer-20, and Cer-22 were associated with a higher risk of developing diabetes in 2 studies of American-Indian adults. This trial was registered at clinicaltrials.gov as NCT00005134.
BACKGROUND: Few studies have assessed the associations of ceramides and sphingomyelins (SMs) with diabetes in humans. OBJECTIVE: We assessed associations of 15 circulating ceramides and SM species with incident diabetes in 2 studies. METHODS: The analysis included 435 American-Indian participants from the Strong Heart Study (nested case-control design for analyses; mean age: 57 y; 34% male; median time until diabetes 4.3 y for cases) and 1902 participants from the Strong Heart Family Study (prospective design for analyses; mean age: 37 y; 39% male; median 12.5 y of follow-up). Sphingolipid species were measured using stored plasma samples by sequential LC and MS. Using logistic regression and parametric survival models within studies, and an inverse-variance-weighted meta-analysis across studies, we examined associations of 15 ceramides and SM species with incident diabetes. RESULTS: There were 446 cases of incident diabetes across the studies. Higher circulating concentrations of ceramides containing stearic acid (Cer-18), arachidic acid (Cer-20), and behenic acid (Cer-22) were each associated with a higher risk of diabetes. The RRs for incident diabetes per 1 SD of each log ceramide species (μM) were 1.22 (95% CI: 1.09, 1.37) for Cer-18, 1.18 (95% CI: 1.06, 1.31) for Cer-20, and 1.20 (95% CI: 1.08, 1.32) for Cer-22. Although the magnitude of the risk estimates for the association of ceramides containing lignoceric acid (Cer-24) with diabetes was similar to those for Cer-18, Cer-20, and Cer-22 (RR = 1.13; 95% CI: 1.01, 1.26), the association was not statistically significant after correction for multiple testing (P = 0.007). Ceramides carrying palmitic acid (Cer-16), SMs, glucosyl-ceramides, or a lactosyl-ceramide were not associated with diabetes risk. CONCLUSIONS: Higher concentrations of circulating Cer-18, Cer-20, and Cer-22 were associated with a higher risk of developing diabetes in 2 studies of American-Indian adults. This trial was registered at clinicaltrials.gov as NCT00005134.
Authors: E T Lee; T K Welty; R Fabsitz; L D Cowan; N A Le; A J Oopik; A J Cucchiara; P J Savage; B V Howard Journal: Am J Epidemiol Date: 1990-12 Impact factor: 4.897
Authors: Jose Antonio Chavez; William L Holland; Julia Bär; Konrad Sandhoff; Scott A Summers Journal: J Biol Chem Date: 2005-03-17 Impact factor: 5.157
Authors: Leonore Wigger; Céline Cruciani-Guglielmacci; Anthony Nicolas; Jessica Denom; Neïké Fernandez; Frédéric Fumeron; Pedro Marques-Vidal; Alain Ktorza; Werner Kramer; Anke Schulte; Hervé Le Stunff; Robin Liechti; Ioannis Xenarios; Peter Vollenweider; Gérard Waeber; Ingo Uphues; Ronan Roussel; Christophe Magnan; Mark Ibberson; Bernard Thorens Journal: Cell Rep Date: 2017-02-28 Impact factor: 9.423
Authors: Elisa T Lee; Thomas K Welty; Linda D Cowan; Wenyu Wang; Dorothy A Rhoades; Richard Devereux; Oscar Go; Richard Fabsitz; Barbara V Howard Journal: Diabetes Care Date: 2002-01 Impact factor: 19.112
Authors: G Frangioudakis; J Garrard; K Raddatz; J L Nadler; T W Mitchell; C Schmitz-Peiffer Journal: Endocrinology Date: 2010-07-21 Impact factor: 4.736
Authors: Brittanie M Volk; Laura J Kunces; Daniel J Freidenreich; Brian R Kupchak; Catherine Saenz; Juan C Artistizabal; Maria Luz Fernandez; Richard S Bruno; Carl M Maresh; William J Kraemer; Stephen D Phinney; Jeff S Volek Journal: PLoS One Date: 2014-11-21 Impact factor: 3.240
Authors: Annelise M Poss; Benjamin Krick; J Alan Maschek; Benjamin Haaland; James E Cox; Prasoona Karra; Anna R Ibele; Steven C Hunt; Ted D Adams; William L Holland; Mary C Playdon; Scott A Summers Journal: Med (N Y) Date: 2022-06-15
Authors: Rebekah J Nicholson; Marie K Norris; Annelise M Poss; William L Holland; Scott A Summers Journal: Annu Rev Nutr Date: 2022-05-18 Impact factor: 9.323
Authors: Jennifer E Kyle; Lisa M Bramer; Daniel Claborne; Kelly G Stratton; Kent J Bloodsworth; Justin G Teeguarden; Shobhan Gaddameedhi; Thomas O Metz; Hans P A Van Dongen Journal: Nat Sci Sleep Date: 2022-05-21
Authors: Clemens Wittenbecher; Fabian Eichelmann; Estefanía Toledo; Marta Guasch-Ferré; Miguel Ruiz-Canela; Jun Li; Fernando Arós; Chih-Hao Lee; Liming Liang; Jordi Salas-Salvadó; Clary B Clish; Matthias B Schulze; Miguel Ángel Martínez-González; Frank B Hu Journal: Circ Res Date: 2020-12-04 Impact factor: 17.367
Authors: Sagar B Dugani; Luke R Christenson; Jeremiah A Aakre; Hai H Bui; Adrian Vella; Michelle M Mielke Journal: Diabetes Res Clin Pract Date: 2021-07-29 Impact factor: 8.180